Danaher Corporation $DHR Stock: Robeco Schweiz AG Reduces Holdings

Robeco Schweiz AG trimmed its stake in Danaher Corporation (NYSE:DHR) by 10.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 275,980 shares of the conglomerate’s stock after selling 33,704 shares during the quarter. Danaher accounts for 1.1% of Robeco Schweiz AG’s portfolio, making the stock its 26th largest position. Robeco Schweiz AG’s holdings in Danaher were worth $61,143,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. BlackRock Inc. purchased a new position in Danaher during the second quarter valued at approximately $10,492,520,000. Jupiter Topco LLC acquired a new position in Danaher in the 2nd quarter valued at approximately $1,456,317,000. Generation Investment Management LLP purchased a new stake in Danaher in the 2nd quarter worth approximately $1,287,949,000. Bank of America Corp DE purchased a new stake in Danaher in the 2nd quarter worth approximately $993,846,000. Finally, Legal & General Group Plc acquired a new stake in shares of Danaher during the 2nd quarter valued at $801,056,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on DHR. Evercore restated an “outperform” rating and set a $230.00 price target on shares of Danaher in a report on Monday, July 6th. JPMorgan Chase & Co. boosted their target price on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday. Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $275.00 target price on shares of Danaher in a research report on Thursday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $242.91.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
• Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
• Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
• Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
• Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO

Danaher Stock Up 0.3%

Danaher stock opened at $230.36 on Friday. The company has a market capitalization of $162.07 billion, a P/E ratio of 37.70, a P/E/G ratio of 2.88 and a beta of 0.76. The firm’s fifty day simple moving average is $216.32 and its 200-day simple moving average is $197.35. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 0.45. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.19. The business had revenue of $6.55 billion during the quarter, compared to analyst estimates of $6.56 billion. Danaher had a net margin of 16.91% and a return on equity of 11.17%. Danaher’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.89 EPS. Sell-side analysts forecast that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is 26.19%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.